This inhibitory role was further supported by studies demonstrating a reduction of miR-10 expression in both kidney biopsy material isolated from individuals with diabetic nephropathy and in STZ-induced diabetic mice (C57BL/6 J), observations paralleled by increased NLRP3 activation (Ding et al., 2021) and corroborated by studies in miR-10 overexpressing STZ-treated mice, where reduced inflammasome activation attenuated an STZ-induced increase in albuminuria, mesangial expansion and inflammation, culminating in improved kidney function (Ding et al., 2021). This evidence concerns the gene NLRP3 and diabetic kidney disease.